The comparison of antioxidant and haematological properties of N-acetylcysteine and α-lipoic acid in physically active males

Agnieszka Zembron-Lacny¹, Małgorzata Słowinska-Lisowska², Zbigniew Szygula³, Kazimierz Witkowski⁴, Kazimierz Szyszka⁵

¹ Department of Biochemistry, University of Physical Education Poznan, Faculty of Physical Culture Gorzow Wlkp., ²Department of Sport Medicine, University of Physical Education Wroclaw, ³Department of Sport Medicine, University of Physical Education Krakow, ⁴Department of Theory and Methodic of Sports Disciplines, University of Physical Education Wroclaw, ⁵Department of Sport Medicine, University of Physical Education Poznan, Faculty of Physical Culture Gorzow Wlkp. Poland

Corresponding author:
Agnieszka Zembron-Lacny
University of Physical Education Poznan
Faculty of Physical Culture Gorzow Wlkp. Department of Biochemistry
Estkowskiego 13, 66-400 Gorzow Wlkp., Poland
e-mail agzem@gorzow.home.pl
phone/fax 0048 95 7279231

Short title: Effect of NAC and ALA on antioxidant status and erythropoietin
Summary

The aim of this study was to follow up whether the modification of pro-antioxidant status by oral thiol administration such as N-acetylcysteine and α-lipoic acid affects the haematological response.

Twenty eight healthy men participated in two independent experiments. Subjects were randomly assigned to one of four groups: controls (C\textsubscript{NAC} and C\textsubscript{ALA}), N-acetylcysteine (NAC) and α-lipoic acid (ALA). 1200 mg of N-acetylcysteine, 600 mg of α-lipoic acid or placebo were administered for 8 days in two doses.

NAC or ALA administration significantly elevated plasma total antioxidant status (TAS) and reduced protein carbonylation (PC) and lipid peroxidation (TBARS) by more than 30%. The reduced glutathione (GSH) and haematological parameters changed only in response to NAC administration. NAC significantly elevated the level of GSH (+33%), EPO (+26%), Hb (+9%) and Hct (+9%) compared with C\textsubscript{NAC}. The mean corpuscular volume (MCV) and the mean corpuscular haemoglobin (MCH) also increased by more than 12% after NAC. The numerous negative or positive correlations between the measures of TAS, PC, TBARS and haematological parameters were found, which suggest the NAC-induced interaction between pro-antioxidant and haematological values.

Our study has shown that both N-acetylcysteine and α-lipoic acid intake reveal an antioxidant action but only N-acetylcysteine improves the haematological response.

Key words: thiol, oxidative damage, antioxidant, erythropoietin
Introduction

The thiols such as cysteine derivatives, glutathione, lipoic acid and ergothioneine have been exceptional compounds involved in production of reactive oxygen species (ROS) thus tightly regulated the homeostasis, which contributes to gene expression, proliferation, antioxidant defence, erythropoiesis, immunological response etc. (Sen and Packer 2000, Valko et al. 2007).

N-acetylcysteine (NAC) and α-lipoic acid (ALA) as the pro-glutathione dietary supplements has been the focus of intensive research in nutrition in the last few years. Both compounds have been suggested to function as powerful antioxidants. NAC and ALA have shown the ability to direct react with ROS such as hydroxyl radical, hypochlorous acid and singlet oxygen, and indirectly through the reduction of glutathione disulfide, tocopherol radicals and ascorbate. NAC and ALA can work as a redox regulator of myoglobin, prolactin, thioredoxin, glucose transporter protein (GLUT4) and transcription factors such as NF-κB, AP-1 and HIF-1. Moreover, ALA as lipoamid, has functioned as a cofactor in the multienzyme complexes that catalyse the oxidative decarboxylation of α-keto acids such as pyruvate, α-ketoglutarate, and branched chain α-keto acids (Cakatay 2005, Kerksick and Willoughby 2005, Moini et al. 2002, Sen and Packer 2000, Valko et al. 2007).

Even though N-acetylcysteine and α-lipoic acid have been commonly used remedies, their use by physically active persons as a pro-glutathione dietary supplement gives rise to controversy. Firstly, it has been observed that NAC or ALA supplementation prevented the decline of thiol content in muscle, lung and blood, and weakened oxidative damage (Moini et al. 2002, Sen et al. 1994). On the other hand, it has been shown that long-term NAC or ALA administration led to enhancement of lipid peroxidation, mitochondrial damage and inhibition of glycogen synthesis (Cakatay 2005, Childs et al. 2001, Kleinveld et al. 1992, Moini et al. 2002). Secondly, NAC has been marked as a useful compound to regulate the differentiation
of erythroid progenitors (Nagata et al. 2007). It has been also helpful in increasing the plasma EPO concentration in humans before and during hypoxia (Hildebrandt et al. 2002). In another study, NAC and ALA did not demonstrate any modulatory effect on EPO production under hypoxia conditions (Freudenthaler et al. 2002).

Due to the interesting role of thiols in cell metabolism and contradictory information concerning NAC and ALA, the aim of this study was to determine 1) whether an improvement of antioxidant status and reduction of oxidative damage by oral N-acetylcysteine and α-lipoic acid administration equally affect the haematological response and 2) whether there is a direct relationship between total antioxidant status and erythropoietin (EPO) secretion.

**Methods**

Twenty eight healthy and trained males with forced training experience of at least 3 years, physical education students, participated in the randomised, double-blind, placebo-controlled and cross-over studies (tab.1). All the subjects were informed of the aim of the study and were given their written consent for participation in the project. The protocol of the study was approved by the local ethics committee in accordance with the Declaration of Helsinki (2000) of the World Medical Association.

1200 mg of N-acetylcysteine (Hexal AG Germany) - NAC group, 600 mg of α-lipoic acid (Wörwag Pharma Germany) - ALA group or 700 mg of lactose (placebo) - C\(_{NAC}\) and C\(_{ALA}\) groups were administered for eight days in two doses as powder dissolved in 50 ml of water. The participants took the first dose in the morning in a fasted state and the second one 2 hours before an evening meal. The wash-out period between the trials with thiol compounds and placebo was three weeks. Subjects had not taken any antioxidants supplements (vitamins or minerals) for 4 weeks prior to the study. During the 8 day experimental period, the athletes
participated in training according the training program. One day before blood sampling, the subjects did not perform any strenuous exercises.

Blood samples were obtained from an antecubital forearm vein with an anticoagulant (EDTAK2) in the morning in a fasted state. The samples were immediately placed in 4°C temperature after collection. Within 10 min, the blood samples were centrifuged at 2500 g and 4°C for 10 min. Aliquots of plasma were stored at -20°C. All samples were analysed within 7 days.

Total antioxidant status (TAS) of the plasma was measured using method developed by Randox laboratories (UK). The method is based on the formation of 2’-2’-azino-di-[3-ethylbenzthiazoline sulphonate] radical which is measured spectrophotometrically at 600 nm. Detection limit for the TAS kit was 0.21 mmol · l⁻¹ and the intra-assay coefficient of variation (CV) was 2.77%.

Plasma protein carbonyls (PC) were measured by the method of Levine et al. (1990) using 2,4-dinitrophenyl hydrazine. The carbonyl content was calculated using an extinction coefficient of 22000 M⁻¹· l⁻¹· cm⁻¹ and expressed as nmol PC per mg of plasma protein. Protein concentration was determined by the method of Bradford (1976).

Plasma lipid peroxidation products were estimated using the measurement of thiobarbituric acid – reactive substance (TBARS) level according to the method of Buege and Aust (1991). The TBARS level was expressed as nmol of malondialdehyde using 1,1,3,3-tetraethoxypropane as a standard. TBARS detection limit was 0.13 nmol · ml⁻¹. The intra-assay coefficient of variation (CV) for PC and TBARS procedures were <10%.

Blood reduced glutathione concentration was estimated by the method of Beutler et al. (1963) using 5,5’-dithiobis-2-nitrobenzoic acid (DTNB). GSH detection limit for the procedure was 2.5 μg · ml⁻¹ and the intra-assay coefficient of variation (CV) was <10%.
The plasma EPO level was measured using immunoassay system Immulite 2000 DPC (USA). Detection limit for the EPO assay was 0.24 mU \cdot ml^{-1} and the intra-assay CV was 5.9%.

Haemoglobin (Hb), haematocrit (Hct), erythrocytes (RBC), mean corpuscular volume (MCV) and mean corpuscular haemoglobin (MCH) were assessed using ABX Micros OT 16 (France).

Statistics. The results are expressed as mean ± SD, and statistical analysis was carried out by one-way ANOVA. The post-hoc Tukey’s test for multiple comparisons among means was used to compare intergroup differences. Correlations were calculated by the Pearson correlation coefficients. P< 0.05 was accepted as significant.

Results

As it was marked in figures 1-3, administration with NAC or ALA significantly improved plasma antioxidant defence and reduced oxidative damage. Total antioxidant status was significantly elevated by both NAC and ALA. In NAC group, an increase in TAS was 38% compared with C_{NAC}, and in ALA group was 9% compared with C_{ALA}. This has shown that an influence of N-acetylcysteine on total antioxidant status was 4-fold higher than \alpha-lipoic acid (fig.1). NAC and ALA revealed a distinct antioxidant action in relation to plasma protein carbonylation and lipid peroxidation products. NAC or ALA administration induced significant decrease in PC by 28% compared with C_{NAC} and C_{ALA} (fig.2). TBARS concentration reached almost 40% declines in NAC and ALA groups in relation to controls (fig.3). In NAC group, TAS indirectly correlated with PC (r = -0.746, P < 0.001) and TBARS (r = -0.562, P < 0.01). In ALA group, the values of correlation coefficients were smaller i.e. r = -0.402 (P < 0.05) for TAS and PC, and r = -0.456 (P < 0.05) for TAS and TBARS.
NAC administration remarkably affected reduced glutathione concentration. NAC elevated GSH level by 33% compared with \( C_{\text{NAC}} \) whereas ALA did not cause any changes in GSH (tab.2). In NAC group, reduced glutathione concentration directly correlated with TAS \((r = 0.549, P < 0.01)\).

Haematological parameters markedly responded to NAC administration (tab.2). NAC significantly elevated the plasma of EPO (+26%), Hb (+9%) and Hct (+9%) compared with \( C_{\text{NAC}} \). The mean corpuscular volume (MCV) and the mean corpuscular haemoglobin (MCH) increased by 12% following NAC whereas erythrocyte count did not change in relation to \( C_{\text{NAC}} \). The numerous negative or positive correlations between the measures of antioxidant status, oxidative damage markers (PC and TBARS) and haematological parameters were found, which suggest the NAC-induced interaction between pro-antioxidant and haematological response (tab.3). ALA administration did not induce any changes in levels of EPO, Hb, Hct, RBC, MCV and MCH, and any relationships between antioxidant status and haematological response.

**Discussion**

The main purpose of the present study was to determine the effects of eight-day thiol compounds administration on plasma pro-antioxidant status and haematological response, and the possible relationship between antioxidant status and EPO level. Both NAC and ALA administration elevated plasma total antioxidant status but an increase in TAS was 4-fold higher in NAC than in ALA group. This could be related to fast and active transport of NAC into cells, deacylation and use of in glutathione synthesis and then the releasing of cysteine or glutathione from cells to plasma. The study of Nielsen *et al.* (2001) have demonstrated a high cysteine level in plasma after three-day NAC supplementation (6 g · d\(^{-1}\)) in athletes. Medved *et al.* (2003) have shown that pre-exercise N-acetylcysteine infusion increased blood glutathione
during sprint test and recovery. Contrary to NAC, ALA has been an autonomous element of plasma total antioxidant status, not as a substrate to glutathione synthesis. ALA can increase GSH concentration only through reduction of disulphide glutathione and increase in cystine utilization (Han et al. 1997).

The study has demonstrated two markers of oxidative damage, the carbonyl groups (PC) and thiobarbituric acid reactive substances (TBARS). Although the TBARS and PC have been non-specific techniques, using them can offer an empirical view on the complex process of lipid peroxidation and protein carbonylation. The reduction of peroxidation and carbonylation, followed by thiol compounds, was observed by many authors (Ates et al. 2008, Hagen et al. 2002, Niess et al. 2004, Marsh et al. 2006). In present study, NAC or ALA administration markedly declined the plasma PC and TBARS levels compared with controls. Moreover, both markers of oxidative damage indirectly correlated with total antioxidant status. This means that thiol supplementation significantly enhances antioxidant defence and reduces oxidative damage in tissues. This also points out that the applied doses of NAC and ALA are optimal and did not induce lipid peroxidation. Childs et al. (2001), Kleinveld et al. (1992) and Moini et al. (2002) have demonstrated temporal increase in peroxidation after NAC or ALA administration. The excess of thiols can cause the thiol auto-oxidation which is potential source of reactive oxidants and may contribute to the cytotoxicity of reactive thiols such as cysteine and cysteamine (Winterbourn et al. 2002). According to Winterbourn et al. (2002) the auto-oxidation of thiols is catalysed by superoxide dismutase and can be enhanced by iron and other transition metal ions. Furthermore, the reaction can be additionally reinforced by vitamin C with ensuing ROS production. Presumably, vitamin C was the main reason for the 30% increase in plasma lipid peroxidation in the study performed by Childs et al. (2001). The authors applied the standard dose of NAC (10 mg · kg⁻¹) and standard period of supplementation (7 days) but used high dose of vitamin C (12.5 mg · kg⁻¹). Therefore, in
our opinion a long-term and high thiol intake with compounds that can generate reactive oxidants should not be recommended to physically active persons.

Contrary to expectations, only NAC administration resulted in an elevation of the GSH concentration. This result is similar to other described in the literature. Medved et al. (2003) have observed that intravenous NAC infusion increased in GSH and decreased in GSSG levels. Matuszczak et al. (2005) have reported that oral NAC intake caused an increase in erythrocyte GSH and plasma cysteine. Formerly, Sen et al. (1994) have found that treatment with 800 mg NAC for 3 days diminished blood glutathione oxidation and lipid peroxidation, and also increased reduced glutathione and enhanced the net peroxyl radical scavenging capacity of the plasma.

The most interesting results of our study have been the positive correlations between plasma total antioxidant status and haematological response in subjects receiving NAC but not ALA. Recently, it has been shown that EPO production and erythroid differentiation are regulated by ROS, especially H$_2$O$_2$, which are involved in redox-sensitive signalling pathways through down-regulation of transcription factors (Fandrey et al. 1994, Huang et al. 1996, Nagata et al. 2007). This means that ROS generation can suppress EPO synthesis whereas antioxidants can stimulate its synthesis. Hildebrandt et al. (2002) were the first to demonstrate that EPO secretion may be modulated by exogenous thiols such as NAC. Our results have confirmed suggestions concerning the relationship between oxidative stress and erythropoiesis and have suggested that only some antioxidants could modulate haematological response.

Earlier, the others researchers made an attempt to evaluate an effect of different antioxidants, such as β-carotene, desferrioxamine, tea polyphenols, α-tocopherol, ascorbic acid, reduced glutathione, N-acetylcysteine and α-lipoic acid, on haematological alterations or EPO gene expression under normoxia or hypoxia conditions (Freudenthaler et al. 2002,
Hildebrandt et al. 2002, Jelkmann et al. 1997, Niess et al. 2004, Senturk et al. 2005, Zhang et al. 2006). Our study has shown that only NAC modulated the haematological response whereas ALA administration did not induce any changes in EPO and other haematological parameters levels. Moreover, ALA also did not increase in GSH concentration, even though it influenced on total antioxidant status and oxidative damage markers. This has suggested that reduced glutathione could be main compound linking the ROS and EPO production.

In summary, eight–day administration with 1200 mg N-acetylcysteine or 600 mg α-lipoic acid 1) led to improvement of total antioxidant status and the reduction in protein carbonylation and lipid peroxidation, 2) confirmed a significant role of NAC in regulation of haematological response, 3) revealed the relationship between changes in plasma total antioxidant status and haematological parameters, 4) disqualified ALA as thiol compound which could affect EPO secretion.

Acknowledgments

This study was supported by grant for research from University of Physical Education Poznan, Poland. We thank Bogusława Wisniewska and Grzegorz Sniegula for technical and analytical assistance.

References


**Table 1.** Physical characteristics of subjects.

<table>
<thead>
<tr>
<th>Group</th>
<th>Age (yr)</th>
<th>Body mass (kg)</th>
<th>Height (cm)</th>
<th>Body fat %</th>
</tr>
</thead>
<tbody>
<tr>
<td>C_NAC/NAC</td>
<td>20.3 ± 2.3</td>
<td>83.4 ± 14.4</td>
<td>178.6 ± 8.5</td>
<td>16.5 ± 4.5</td>
</tr>
<tr>
<td>(n = 15)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C_ALA/ALA</td>
<td>25.5 ± 6.0</td>
<td>86.4 ± 8.1</td>
<td>180.5 ± 5.9</td>
<td>14.1 ± 3.9</td>
</tr>
<tr>
<td>(n = 13)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 2.** The post-intervention levels of reduced glutathione (GSH) and haematological parameters.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>C_NAC</th>
<th>NAC</th>
<th>C_NAC vs. NAC</th>
<th>C_ALA</th>
<th>ALA</th>
<th>C_ALA vs. ALA</th>
</tr>
</thead>
<tbody>
<tr>
<td>GSH mg·gHb⁻¹</td>
<td>1.54 ± 0.25</td>
<td>2.05 ± 0.25</td>
<td>P&lt;0.01</td>
<td>1.94 ± 0.18</td>
<td>2.00 ± 0.22</td>
<td>ns</td>
</tr>
<tr>
<td>EPO U·l⁻¹</td>
<td>8.91 ± 1.95</td>
<td>11.23 ± 3.02</td>
<td>P&lt;0.01</td>
<td>7.42 ± 1.70</td>
<td>8.81 ± 2.04</td>
<td>ns</td>
</tr>
<tr>
<td>Hb g·dl⁻¹</td>
<td>14.51 ± 0.72</td>
<td>16.00 ± 0.93</td>
<td>P&lt;0.001</td>
<td>14.85 ± 0.80</td>
<td>14.39 ± 0.75</td>
<td>ns</td>
</tr>
<tr>
<td>Hct %</td>
<td>42.51 ± 2.67</td>
<td>46.55 ± 2.87</td>
<td>P&lt;0.01</td>
<td>42.07 ± 2.44</td>
<td>42.22 ± 2.11</td>
<td>ns</td>
</tr>
<tr>
<td>RBC 10⁶·μl⁻¹</td>
<td>5.42 ± 0.34</td>
<td>5.29 ± 0.38</td>
<td>ns</td>
<td>5.27 ± 0.31</td>
<td>5.16 ± 0.24</td>
<td>ns</td>
</tr>
<tr>
<td>MCV fl</td>
<td>78.50 ± 2.10</td>
<td>88.07 ± 2.63</td>
<td>P&lt;0.001</td>
<td>80.00 ± 3.08</td>
<td>80.00 ± 3.81</td>
<td>ns</td>
</tr>
<tr>
<td>MCH gm·dl⁻¹</td>
<td>26.84 ± 1.16</td>
<td>30.29 ± 0.90</td>
<td>P&lt;0.001</td>
<td>28.21 ± 1.18</td>
<td>27.93 ± 1.45</td>
<td>ns</td>
</tr>
</tbody>
</table>

C_NAC and C_ALA – controls; NAC – N-acetylcysteine, ALA - α-lipoic acid; C_NAC vs. NAC and C_ALA vs. ALA indicate statistical differences between control and supplemented groups.
Table 3. The relationships between total antioxidant status and haematological parameters observed in study with N-acetylcysteine.

<table>
<thead>
<tr>
<th></th>
<th>EPO</th>
<th>Hb</th>
<th>Hct</th>
<th>RBC</th>
<th>MCV</th>
<th>MCH</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAS</td>
<td>r = 0.448*</td>
<td>r = 0.637*</td>
<td>r = 0.565*</td>
<td>r = -0.177</td>
<td>r = 0.841*</td>
<td>r = 0.753*</td>
</tr>
<tr>
<td></td>
<td>P &lt; 0.05</td>
<td>P &lt; 0.01</td>
<td>P &lt; 0.01</td>
<td>P &gt; 0.05</td>
<td>P &lt; 0.001</td>
<td>P &lt; 0.001</td>
</tr>
<tr>
<td>PC</td>
<td>r = -0.520*</td>
<td>r = -0.499*</td>
<td>r = -0.446*</td>
<td>r = 0.111</td>
<td>r = -0.660*</td>
<td>r = -0.569*</td>
</tr>
<tr>
<td></td>
<td>P &lt; 0.01</td>
<td>P &lt; 0.05</td>
<td>P &lt; 0.05</td>
<td>P &gt; 0.05</td>
<td>P &lt; 0.001</td>
<td>P &lt; 0.01</td>
</tr>
<tr>
<td>TBARS</td>
<td>r = -0.368</td>
<td>r = -0.622*</td>
<td>r = -0.448*</td>
<td>r = -0.108</td>
<td>r = -0.369</td>
<td>r = -0.436*</td>
</tr>
<tr>
<td></td>
<td>P &gt; 0.05</td>
<td>P &lt; 0.001</td>
<td>P &lt; 0.05</td>
<td>P &gt; 0.05</td>
<td>P &gt; 0.05</td>
<td>P &lt; 0.05</td>
</tr>
</tbody>
</table>

*P < 0.05

Figure 1. Post-intervention changes in total antioxidant status (TAS); C_{NAC} and C_{ALA} - placebo; NAC - N-acetylcysteine, ALA - α-lipoic acid; *P<0.05, **P<0.01 and ***P<0.001 indicate statistical differences between controls and supplemented groups.
Figure 2. Post-intervention changes in protein carbonylation products (PC); CNAC and CALA - placebo; NAC - N-acetylcysteine, ALA - α-lipoic acid; *P<0.05, **P<0.01 and ***P<0.001 indicate statistical differences between controls and supplemented groups.

Figure 3. Post-intervention changes in lipid peroxidation products (TBARS); CNAC and CALA - placebo; NAC - N-acetylcysteine, ALA - α-lipoic acid; *P<0.05, **P<0.01 and ***P<0.001 indicate statistical differences between controls and supplemented groups.